Apellis Pharmaceuticals, Inc.
pegcetacoplan
geographic atrophy (GA)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on pegcetacoplan for geographic atrophy (GA) is in focus around Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“SYFOVRE is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with hypersensitivity to pegcetacoplan or any of the excipients in SYFOVRE.”